Merck (MRK -0.1%) gives back early gains despite its Q1 EPS beating estimates this morning. Net...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK -0.1%) gives back early gains despite its Q1 EPS beating estimates this morning. Net profit jumped 67% Y/Y on lower costs, but a slowdown in sales growth for blockbuster diabetes drug Januvia curtailed overall revenue growth. The drug maker also reaffirms its FY12 earnings targets, and says it seeking a remedy to the overcome impact of its impending Singulair patent expiry.